Previous Close | 137.83 |
Open | 137.83 |
Bid | 137.92 x 200 |
Ask | 138.02 x 200 |
Day's Range | 135.97 - 138.72 |
52 Week Range | 89.04 - 148.37 |
Volume | |
Avg. Volume | 874,862 |
Market Cap | 13.724B |
Beta (5Y Monthly) | 0.24 |
PE Ratio (TTM) | 55.84 |
EPS (TTM) | 2.47 |
Earnings Date | May 01, 2024 - May 06, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | Dec 29, 1995 |
1y Target Est | 151.20 |
Neurocrine Biosciences, Inc. (Nasdaq: NBIX), today announced the initiation of its Phase 1 clinical study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of investigational compound NBI-1065890 in healthy adult participants. NBI-1065890 is an investigational, oral, selective inhibitor of the vesicular monoamine transporter-2 (VMAT2) for the potential treatment of certain neurological and neuropsychiatric conditions.
S&P 500 stocks DexCom, Blackstone and Royal Caribbean lead five stocks around buy points after Fed chief Jerome Powell helped buoy markets.
The major indexes faded from record highs as Apple fell on a DOJ lawsuit. But many stocks flashed buy signals. Lululemon, FedEx and Nike reported late.